Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (551-560 of 692) with videos related to

Pageof 70
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PETBradley J Beattie, Peter M Smith-Jones, Yuliya S Jhanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Cancer Research|August 19, 2017
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancerS F Slovin, H I Scher, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancerHoward I Scher, Xiaoyu Jia, Kim Chi, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2018
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate CancerLiana B Guedes, Carlos L Morais, Helen Fedor, et al.
Nature Reviews. Urology|July 9, 2026
Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancerSean A Fletcher, Nicholas A Pickersgill, Juan C Osorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Susceptibility loci associated with prostate cancer progression and mortalityDavid J Gallagher, Joseph Vijai, Angel M Cronin, et al.
Prostate Cancer and Prostatic Diseases|February 26, 2020
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancerSounak Gupta, Chad Vanderbilt, Wassim Abida, et al.
Pageof 70

Showing results (551-560 of 692) with videos related to

Sort By:
Pageof 70
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PETBradley J Beattie, Peter M Smith-Jones, Yuliya S Jhanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.
Cancer Research|August 19, 2017
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancerS F Slovin, H I Scher, C R Divgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancerHoward I Scher, Xiaoyu Jia, Kim Chi, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2018
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate CancerLiana B Guedes, Carlos L Morais, Helen Fedor, et al.
Nature Reviews. Urology|July 9, 2026
Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancerSean A Fletcher, Nicholas A Pickersgill, Juan C Osorio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Susceptibility loci associated with prostate cancer progression and mortalityDavid J Gallagher, Joseph Vijai, Angel M Cronin, et al.
Prostate Cancer and Prostatic Diseases|February 26, 2020
Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancerSounak Gupta, Chad Vanderbilt, Wassim Abida, et al.
Pageof 70